All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma

CAR-T or stem cell transplant for second-line treatment of aggressive B-cell NHL?

Apr 2, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma/CLL

During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak with Mehdi Hamadani, Medical College of Wisconsin, Milwaukee, US. We asked, CAR-T or stem cell transplant for second-line treatment of aggressive B-cell non-Hodgkin lymphoma (NHL)?

CAR-T or stem cell transplant for second-line treatment of aggressive B-cell NHL?

Hamadani begins by outlining the current treatment approaches, however, he explains the problems faced by high-risk patients and those who relapse early. He goes on to discuss three recent randomized studies investigating alternative treatments to improve outcomes for these patients (TRANSFORM, ZUMA, and BELINDA). Finally, Hamadani addresses how he would apply these findings to his own clinical practice, and makes some recommendations for certain treatment settings.

 

Share: